Normal linear growth in hypophosphataemic bone disease

Area of Science:

• Endocrinology
• Metabolic Bone Disease
• Pediatric Nephrology

Background:

• Hypophosphatemic bone diseases are a group of inherited or acquired disorders characterized by impaired renal phosphate reabsorption.
• Treatment typically involves phosphate (PO4) supplementation and active vitamin D metabolites to normalize serum phosphate levels and promote bone mineralization.

Observation:

• This report describes a specific case of hypophosphatemic bone disease with a prolonged, seven-and-a-half-year follow-up period.
• The patient received standard therapeutic interventions, including oral phosphate supplements and 1.25-dihydroxycholecalciferol (a vitamin D analog).

Findings:

• Despite consistent therapeutic efforts, the patient exhibited persistently low serum PO4 levels throughout the observation period.
• A diminished theoretical renal threshold for phosphate (TmPO/GFR) was noted, indicating a persistent issue with renal phosphate handling.
• Notably, the patient's linear growth trajectory remained within normal parameters despite the biochemical abnormalities.

Implications:

• This case highlights the potential for treatment resistance in certain hypophosphatemic bone disease presentations.
• It underscores the importance of monitoring both biochemical markers and linear growth in managing these conditions.
• Further research may be warranted to explore alternative or adjunctive therapeutic strategies for refractory cases.